GlassScriptPhysician profile
Vivek U Rao
NPI 1629084504
$3,405.68
in general payments reported to CMS, 2019-2025
18 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $56.67 · 2021: $312 · 2022: $15.60 · 2023: $97.41 · 2024: $1,079 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.27 |
| Education | $194.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $934.25 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Pharming Healthcare, INC. | $529.47 | 2024-2025 | Ruconest, Joenja |
| Glaxosmithkline, LLC. | $355.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Alk-Abello, INC | $271.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $215.82 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $202.89 | 2024-2025 | Dupixent |
| Adma Biomanufacturing LLC | $137.68 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $125.04 | 2021 | |
| Aquestive Therapeutics, INC. | $103.38 | 2024 | |
| Greer Laboratories, INC. | $95.57 | 2025 | Oralair |
| Csl Behring | $87.99 | 2019-2025 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $76.68 | 2021-2025 | Takhzyro |
| Biocryst US Sales Co., LLC | $67.79 | 2024 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $61.18 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $48.81 | 2025 | Neffy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $48.04 | 2019 | |
| Blueprint Medicines Corporation | $24.87 | 2023 | Ayvakit |
| Hikma Pharmaceuticals USA | $19.78 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.